Structure-activity relationship of 2-arylquinolines as PET imaging tracers for tau pathology in Alzheimer disease

Journal of Nuclear Medicine

Volumn 57, Issue 4, 2016, Pages 608-614

  Tago, Tetsuro ^a   Furumoto, Shozo ^a   Okamura, Nobuyuki ^b   Harada, Ryuichi ^a   Adachi, Hajime ^a   Ishikawa, Yoichi ^a   Yanai, Kazuhiko ^a,b   Iwata, Ren ^a   Kudo, Yukitsuka ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Positron emission tomography; Structure activity relationship; Tau proteins

Indexed keywords

2 ARYLQUINOLINE; 2 ARYLQUINOLINE FLUORO POLYETHYLENEGLYCOL F 18; 2 ARYLQUINOLINE FLUOROETHOXY F 18; 2 ARYLQUINOLINE FLUOROPROPOXY F 18; BENZENE; QUINOLINE DERIVATIVE; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG; FLUORINE; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN HOMOGENATE; CHEMICAL BINDING; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DEFLUORINATION; ENANTIOMER; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; MALE; METABOLITE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNTHESIS; VERY ELDERLY; ANIMAL; BRAIN; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; SCINTISCANNING; TAUOPATHY; TISSUE DISTRIBUTION;

ALZHEIMER DISEASE; ANIMALS; AUTORADIOGRAPHY; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; MICE; POSITRON-EMISSION TOMOGRAPHY; PREGNANCY; PROTEIN BINDING; QUINOLINES; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; TAU PROTEINS; TAUOPATHIES; TISSUE DISTRIBUTION;

EID: 84963972230     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.166652     Document Type: Article

References (32)

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
2. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700-1725.
3. Goedert M, Spillantini MC, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron. 1989;3:519-526.
4. Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.
5. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15:112-119.
6. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
7. Svedberg MM, Rahman O, Hall H. Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease. Nucl Med Biol. 2012;39:484-501.
8. Zwan MD, Okamura N, Fodero-Tavoletti MT, et al. Voyage au bout de la nuit: Ab and tau imaging in dementias. Q J Nucl Med Mol Imaging. 2014;58:398-412.
9. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114-124.
10. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14:500.
11. Chien DT, Bahri S, Szardenings a K, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457-468.
12. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094-1108.
13. 18F-THK5105 PET. Brain. 2014;137:1762-1771.
14. Okamura N, Suemoto T, Furumoto S, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci. 2005;25:10857-10862.
15. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134:1089-1100.
16. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420-1427.
17. Tago T, Furumoto S, Okamura N, et al. Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Labelled Comp Radiopharm. 2014;57:18-24.
18. 18F]THK-5117 PET for assessing the neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2015;42:1052-1061.
19. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:816-826.
20. Li Y, Tsui W, Rusinek H, et al. Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med. 2015;56:270-273.
21. Villemagne V, Furumoto S, Fodero-Tavoletti MT, et al. The challenges of tau imaging. Future Neurol. 2012;7:409-421.
22. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740-2754.
23. Simonyi M, Fitos I, Visy J. Chirality of bioactive agents in protein binding storage and transport processes. Trends Pharmacol Sci. 1986;7:112-116.
24. 18F]THK-5105 enantiomers: effects of chirality on its effectiveness as a tau imaging radiotracer. Mol Imaging Biol. July 21, 2015 [Epub ahead of print].
25. Dishino DD, Welch M, Kilbourn M. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med. 1983;24:1030-1038.
26. 18F]fluoroalkyl aryl ester and ether PET tracers. Nucl Med Biol. 2013;40:850-857.
27. Tewson TJ, Welch M. Preparation and preliminary biodistribution of "no carrieradded" fluorine-18 fluoroethanol. J Nucl Med. 1980;21:559-564.
28. 18F]SP203), a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain. J Pharmacol Exp Ther. 2008;327:727-735.
29. 18FFCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain. J Nucl Med. 2007;48: 1154-1161.
30. Graham TJ, Lambert R. Enantioselective radiosynthesis of positron emission tomography (PET) tracers containing fluorohydrins. J Am Chem Soc. 2014;136: 5291-5294.
31. 18F]FMISO. Nucl Med Biol. 2015;42:413-419.
32. 18F-THK-5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer's disease. J Nucl Med. November 5, 2015 [Epub ahead of print].